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Negative-strand (NS) RNA viruses comprise many pathogens that
cause serious diseases in humans and animals. Despite their clinical
importance, little is known about the host factors required for their
infection. Using vesicular stomatitis virus (VSV), a prototypic NS RNA
virus in the family Rhabdoviridae, we conducted a human genomewide siRNA screen and identiﬁed 72 host genes required for viral
infection. Many of these identiﬁed genes were also required for
infection by two other NS RNA viruses, the lymphocytic choriomeningitis virus of the Arenaviridae family and human parainﬂuenza
virus type 3 of the Paramyxoviridae family. Genes affecting different stages of VSV infection, such as entry/uncoating, gene expression, and assembly/release, were identiﬁed. Depletion of the proteins
of the coatomer complex I or its upstream effectors ARF1 or GBF1 led
to detection of reduced levels of VSV RNA. Coatomer complex I was
also required for infection of lymphocytic choriomeningitis virus and
human parainﬂuenza virus type 3. These results highlight the evolutionarily conserved requirements for gene expression of diverse families of NS RNA viruses and demonstrate the involvement of host cell
secretory pathway in the process.
RNA interference
virus infection
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egative-strand (NS) RNA viruses include a large group of
human and animal pathogens that cause diseases ranging
from mild ﬂu-like symptoms to fatal hemorrhagic fever. Vesicular
stomatitis virus (VSV), the prototype of the family Rhabdoviridae,
is an enveloped virus with a nonsegmented NS RNA genome. VSV
infects most vertebrate and many invertebrate cells and has a short
infection cycle. These characteristics have earned appreciation for
VSV as an excellent model for understanding virus entry, genome
uncoating, replication, assembly, and budding processes, as well as
for studying innate and adaptive immune defense mechanisms.
VSV is also used as a viral vaccine vector, as an oncolytic agent,
and for gene therapy (1).
VSV encodes ﬁve proteins: the nucleocapsid protein (N), the
phosphoprotein (P), the matrix protein (M), the glycoprotein (G),
and the large polymerase protein (L) (2). The viral RNA exists in
the virion core as N protein-bound nucleocapsid (NC) to which the
viral polymerase is associated. During infection, VSV binds to
susceptible cells, although the receptor(s) mediating virus entry
remains unidentiﬁed (3). It enters cells by clathrin-mediated endocytosis, requiring endocytic adaptor protein AP-2, actin, and
dynamin (4–6). Once in the cytoplasm, low pH-dependent fusion
of viral envelope with the endosomal membrane leads to the release of NC in the cytoplasm for transcription and replication to
occur. Progeny NCs are transported toward the cell periphery in a
microtubule-dependent manner (7). Assembly of the viral components occurs at the plasma membrane, and nascent virions are
released from the cells.
Viruses use key cellular pathways for their infection and replication (8, 9). Although much is known about the viral proteins in
the biology of the virus, little is known about the host factors in VSV
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and other NS RNA virus infections. Identifying the cellular factors
and studying the mechanisms of their involvement in these viral
infections is important not only for understanding the biology of
these pathogens, but also for development of antiviral therapeutics.
The advent of siRNA technology and the availability of genome-wide siRNA libraries have been useful in identifying host
factors required for inﬂuenza virus, an NS RNA virus, and several
positive-strand RNA viruses, as well as HIV (10–19). The lack of
similar studies with other NS RNA viruses has limited the understanding of the role of host cell factors in replication of these
viruses. Using VSV, we conducted a genome-wide siRNA screen
to identify mammalian genes required for viral infection. Our
studies revealed requirements for several cellular pathways and
proteins in VSV infection. Many of the factors identiﬁed in the
screen for VSV are also required for infection by two other NS
RNA viruses: the human parainﬂuenza virus type 3 (HPIV3), a
nonsegmented NS RNA virus in the family Paramyxoviridae, and
the lymphocytic choriomeningitis virus (LCMV), a segmented
genome NS RNA virus in the family Arenaviridae. Interestingly, for
these three viruses representing diverse families of NS RNA
viruses, viral gene expression required the function of the coatomer complex I (COPI), a coat protein complex involved in retrograde vesicular transport from the Golgi to the endoplasmic
reticulum (ER) (20). Overall, the studies reveal a critical need for
the cellular secretory pathway in gene expression of disparate
families of NS RNA viruses.
Results
Genome-Wide RNAi Screen for Host Factors in VSV Infection. To

identify host proteins required for VSV infection, a genome-wide
siRNA screen was conducted. Four independent siRNAs, grouped
into a 2 × 2 pool format (Fig. 1A), targeting each of 22,909
mammalian genes, were used. VSV-eGFP, a recombinant virus
encoding enhanced green ﬂuorescent protein (eGFP) (7), was
used to infect HeLa cells. Expression of eGFP in the cells would
indicate virus infection and gene expression. AllStars nontargeting
(NT) siRNA and siRNAs targeting the VSV L and N mRNAs
were used as controls. At 52 h post-siRNA transfection (hpt), cells
were infected with VSV-eGFP (hereafter VSV), and at 18 h
postinfection (hpi), they were ﬁxed, stained for nuclei, and processed for automated image analysis. Cell number and percent
infection were obtained for each well. Infection of NT siRNAtransfected cells was optimized to yield, on average, 60% infection
rate. Under these conditions, the rate of infection of cells
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transfected with L and N siRNAs was reproducibly <1% (Fig. 1 B
and C). Wells with low cell number due to combined effects of
siRNA toxicity and VSV cytopathic effects (SI Experimental Procedures) were excluded from further analyses. Sum rank analysis
(21) was used, and 233 host genes (P < 0.01) were identiﬁed as
required for VSV infection.
We found several expected genes, including those of the canonical ribosomal proteins, key parts of the cellular translational
machinery. We deleted the ribosomal protein genes and narrowed
down the list to 173 genes (Dataset S1). Because our screen design
used a 2 × 2 siRNA pool format, the 173 genes exhibited the same
phenotype with at least two different siRNAs (at least one from
each pool), a recommended criterion for true hit identiﬁcation
(22). Thus, the 173 genes identiﬁed may represent factors required
for VSV infection. The biological process categories of cellular
genes overrepresented in the list based on the Panther classiﬁcation system (23) include genes involved in metabolic processes,
nucleic acid metabolism, intracellular protein transport, vesiclemediated transport, and exocytosis, among others (Fig. 1D).
Pathway analysis revealed that protein functions involved in at
least eight major cellular pathways were signiﬁcantly enriched and
showed possible interconnections between these pathways for
VSV infection (Fig. S1A). Comparison of the mammalian genes
identiﬁed from genome-wide siRNA screens for other RNA
viruses (10–13, 15, 16, 24, 25) with those from the VSV screen
revealed that genes in several major biological functions categories
are shared by RNA viruses (Fig. S1B).
We then conducted a validation screen for the 173 identiﬁed
genes using siRNAs from another source, Dharmacon ONTARGETplus pool of four siRNAs. The validation screen was
performed in four replicates, and analysis of the results (SI Experimental Procedures) led to identiﬁcation of 72 out of the 173
genes as required for VSV infection (Fig. 1F and Dataset S2).
HPIV3 and LCMV Infection Share Many Factors Required for VSV
Infection. To identify genes and pathways used by diverse families

of NS RNA viruses, the involvement of the 72 genes identiﬁed for
VSV was examined in HPIV3 and LCMV infection. These viruses
belong to distinct families of NS RNA viruses and have common as
Panda et al.

well as unique strategies for entry, uncoating, replication, and virus
assembly. GFPs expressing LCMV and HPIV3 (26, 27) were used,
and the screen was conducted as described for VSV in duplicate.
By using this strategy, 54 and 27 genes were identiﬁed as required
for LCMV and HPIV3 infection, respectively, whereas 25 genes
were required for infection by all three viruses (Fig. 1E). The genes
identiﬁed for infection by the three viruses along with their known
and putative functions, can be found in Datasets S2 and S3, respectively. The normalized percent infection for the 72 genes
identiﬁed as required for VSV are shown in the heat map (Fig. 1F)
and are compared with those found for LCMV and HPIV3.
Identiﬁcation of Genes Involved in Various Stages of VSV Infection.

The screen used a multicycle VSV infection assay that included all
stages of the virus infection cycle, such as entry and uncoating,
transcription and replication, and assembly and release. Our
screen identiﬁed several subunits of vATPase as necessary for
VSV infection (Fig. 1F and Fig. S2), conﬁrming the known role of
vATPase in endocytosis and virus uncoating (28).
The screen identiﬁed several solute carriers localized to the
plasma membrane, including the solute carrier family 46 member 1
[SLC46A1; proton-coupled folate transporter (PCFT)]. We examined the role of SLC46A1 in VSV infection. Results showed
that in siRNA-treated cells infected with VSV or VSVΔG [a virus
that lacks the G gene and cannot produce infectious virus, so the
infection with this virus is limited to single cycle only (29)], VSV
gene expression (levels of M protein) was reduced (Fig. 2A). We
then transfected VSV NC to cells treated with siRNAs for
SLC46A1 to bypass the endosome-mediated entry and uncoating
and examined the effects of depletion of the protein on gene expression. VSV NCs are not infectious per se when added to cells
but can initiate the viral genome transcription and replication
when delivered into the cytoplasm by transfection. Results show
that virus gene expression from transfected NCs remained unaffected (Fig. 2A). Multiple siRNAs from two different sources
also led to reduced viral gene expression as well as depletion of the
SLC46A1 protein (Fig. S3A), indicating that the inhibitory effect
is speciﬁc. Together, these results suggest that SLC46A1 may be
required for VSV entry and/or uncoating.
PNAS | November 22, 2011 | vol. 108 | no. 47 | 19037
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Fig. 1. The RNAi screen. (A) Schematic of the RNAi screen. (B) Representative images of cells treated with AllStars NT, L, and N siRNAs and infected with VSV-eGFP. (C)
Bar graph showing the percent infection (mean ± SD) of cells for control siRNAs in the genomic screen. (D) Overrepresented Panther categories of biological processes
of cellular genes identiﬁed in the screen. The number of genes in each category and statistical signiﬁcance (P) are shown. (E) The extent of overlap among the
validated genes for VSV, LCMV, and HPIV3 is shown in the Venn diagram. (F) Percent infections for the validated genes normalized to that of NT siRNA are presented
as a heat map. Data represents average of four experiments for VSV and two experiments for LCMV and HPIV3. Genes required for all three viruses are shown in red.
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To identify genes involved in virus assembly and release, we
screened the 72 genes using both multicycle (with VSV) and single-cycle (with VSVΔG) infection assays. We found that in ADAL
(Adenosine Deaminase Like) siRNA-treated cells infected with
VSV, the percent infection was ~threefold less compared with the
NT siRNA-treated cells, whereas the percent infection of cells
with VSVΔG was similar in both ADAL and NT siRNA-treated
cells (Fig. 2B). We found no differences in the level of viral gene
expression in cells treated with either siRNAs and infected with
either VSVΔG or VSV (Fig. 2C). However, infectious virus production was reduced in VSV-infected cells treated separately with
two different sources of ADAL siRNA (Fig. 2D). These results
suggest that ADAL may facilitate VSV assembly and/or release.
Further, we found that methionine adenosyltransferase 2A
(MAT2A) siRNA treatment reduced VSV gene expression signiﬁcantly (Fig. 2E). MAT2A is involved in L-methionine metabolism and catalyzes formation of S-adenosylmethionine (30). MAT2A
siRNA treatment also reduced gene expression in cells infected with
VSVΔG or in cells transfected with NCs (Fig. 2E). Multiple siRNAs
for MAT2A led to depletion of the MAT2A protein and corresponding reduction in VSV gene expression (Fig. 2F). Viral mRNA
and anti-genome levels were reduced in cells treated with MAT2A
siRNA (Fig. S3B). These results indicate that MAT2A may have a
role in viral gene expression.
COPI Is Necessary for VSV Infection at the Level of Viral Gene
Expression. Network analysis revealed vesicle trafﬁcking as one of

the top scoring pathways required for infection. COPI is involved
in retrograde vesicular transport of luminal and membrane proteins from the Golgi to the ER and intra-Golgi transport (20). We
focused on COPI because multiple proteins in this pathway were
identiﬁed and siRNAs for COPI subunits (except COPE) exhibited strong inhibition of VSV infection (Fig. 1F). Fig. 3A shows
inhibition in VSV infection in cells treated with COPZ1 or
COPB1 siRNAs.
Because the early secretory pathway is necessary for VSV G
protein processing (31), it is possible that the COPI depletion
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Fig. 2. Identiﬁcation of genes for VSV entry/uncoating, assembly/budding,
and gene expression. (A) Cells were transfected with SLC46A1 siRNA for 72 h
and infected with viruses (VSV, 0.005 MOI; VSVΔG, 0.2 MOI) or transfected
with NC. Cell extracts prepared at 14 hpi (VSV), 5 hpi (VSVΔG), or 6 hpt (NC)
were examined for M expression. (B) Experiment was performed as in A by
using ADAL siRNAs, and percent infection was determined. Values are normalized to NT siRNA and represent mean ± SD from three experiments. (C)
Cells transfected with ADAL siRNA were infected with VSV (0.1 MOI) or
VSVΔG (0.2 MOI), and M protein expression was examined at 5 hpi. (D)
Relative VSV yield (mean ± SD) at 14 hpi (0.001 MOI) after ADAL siRNAs from
Dharmacon (ADAL-D) or Qiagen (ADAL-Q) treatment from three experiments. (E) Effect of siRNA for MAT2A on viral gene expression in cells
infected with VSV or VSVΔG or transfected with NCs. Experimental conditions are as in A. (F) Cells were transfected with individual siRNA duplexes
(Dharmacon) for MAT2A and infected with VSV (0.005 MOI) for 12 h. Cell
lysates were examined for levels of M, actin, and MAT2A proteins.
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Fig. 3. COPI is required for VSV, LCMV, and HPIV3 infection. (A) HeLa cells
transfected with siRNAs for COPI subunits were infected with VSV (MOI = 0.01),
and at 14 hpi, they were ﬁxed, stained with DAPI, and imaged at 10× magniﬁcation. (B) Cells transfected with siRNAs for COPI subunits for 48 h were
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above were infected with VSVΔG virus. At 5 hpi, viral gene expression was
assessed by immunoblotting for M. (D) Cells transfected with individual siRNAs
were infected with VSV for 4 h. VSV gene expression (M level) and COPZ1 levels
were assessed by immunoblotting. (E) Cells pretreated with CBM for 1 h were
infected with VSV as in B, and viral gene expression was assessed by immunoblotting for M. (Right) Histogram shows relative levels of viral gene expression from three experiments. (F) VSV NCs were transfected into cells
treated with siRNAs for COPZ1 and ARCN1. At 6 h after NC transfection, viral
gene expression was examined by immunoblotting for M. (G) VSV mRNA and
anti-genomic RNA levels in COPZ1-depleted cells, determined by qRT-PCR using
primers and probe concentrations shown in Tables S1 and S2 (SI Experimental
Procedures). Experimental conditions were as in B. Values show mean ± SE of
measurement (SEM) of duplicate reactions from two experiments after normalizing to NT control. (H) Cells infected with VSV as in B were treated with 2
mM CBM at 1 hpi. Viral mRNA and anti-genome levels were determined as in G.
(I) Cells transfected with siRNAs for COPI as in B were infected with 1 MOI of
LCMV for 7 h or HPIV for 14 h. Viral gene expression was assayed by immunoblotting for eGFP or Renilla reniformis-GFP (GFPrr).

might have affected G protein processing and, consequently, virion
assembly and release. To determine whether COPI plays any role
in other steps of the VSV infection cycle, we examined the effect of
COPI subunit siRNAs on VSV gene expression at 4 hpi, a time at
which viral gene expression is readily detectable. At this time, VSV
gene expression was inhibited by all COPI siRNAs (except COPE)
(Fig. 3B). Furthermore, VSVΔG virus infection of cells depleted of
COPZ1 and COPB1 showed a signiﬁcant reduction of viral gene
expression (Fig. 3C), indicating that COPI plays a role in facilitating
viral entry, uncoating, and/or gene expression. The degree of inhibition of VSV gene expression correlated with the level of depletion of COPZ1 (Fig. 3D) and COPB1 (Fig. S4A). Multiple siRNA
for each of the COPI subunits (except COPE) reduced VSV gene
expression (Fig. S4B). We then used 1,3-cyclohexanebismethylamine
(CBM), an inhibitor of COPI function (32, 33), to examine involvement of COPI in VSV gene expression. Treatment of cells with
CBM 1 h before infection reduced VSV M protein levels in a dosedependent manner (Fig. 3E) without adversely affecting the cell viability (Fig. S5). These studies suggest that COPI is necessary for
VSV infection.
Panda et al.
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quired for the recruitment of COPI complex onto the Golgi
membranes (36). In ARF1 siRNA-treated cells infected with
VSV, the viral gene expression was reduced by twofold with
concomitant similar reduction in the levels of ARF1 protein (Fig.
4A and Fig. S6A), suggesting that moderate inhibition of viral gene
expression may be due to insufﬁcient depletion of ARF1. In cells
transfected with a plasmid encoding a dominant-negative mutant,
ARF1-T31N (37), viral gene expression was inhibited (Fig. 4B).
ARF1 depletion also inhibited LCMV gene expression but surprisingly had no effect on HPIV3 gene expression (Fig. 4C). It is
possible that moderate level of ARF1 depletion might not have
shown measurable inhibitory effect on HPIV3 gene expression.
The Golgi-associated brefeldin A resistant factor 1 (GBF1) is
the guanine nucleotide exchange factor, which catalyzes GDP–
GTP exchange to activate ARF1 for COPI recruitment onto the
Golgi membranes (38). GBF1 siRNA reduced endogenous
GBF1 protein levels by >90% and led to signiﬁcant reduction in
VSV M protein (Fig. 4D). Reduction in VSV mRNA and antigenome levels was observed after GBF1 depletion (Fig. S6B),
suggesting that VSV gene expression requires GBF1.

GBF1

Viral Gene Expression Requires ARF1 and GBF1, the Upstream Effectors
of COPI. Activation of ADP ribosylation factor 1 (ARF1) is re-

DMSO

Discussion
In the present study, using a genome-wide siRNA screen, we have
identiﬁed host cell factors required for VSV infection. Because of
our screen design (2 × 2 pool of siRNA format) and validation
using a different source of siRNAs, the possibility of false positives
in the list is likely to be low, but it may have compromised our
ability to identify additional genes required for VSV infection. An
integrated model (Fig. 5) revealing the host factors required for
VSV infection demonstrates many previously undescribed functions and pathways used not only by VSV but also by other RNA
viruses such as LCMV and HPIV3. This study provides a comparative analysis of cellular factors involved in replication of three
disparate NS RNA viruses. Functions such as RNA processing,
vesicular transport, transcription, and translation regulations, among
others, are shared by all three viruses, which would suggest utilization of common cellular functions for their replication. It should be
noted that the factors identiﬁed for LCMV and HPIV3 are only
a subset of those identiﬁed for VSV and do not represent a complete
set of factors required for either LCMV or HPIV3. However, it is
evident that several of the cellular pathways and factors are shared
by all three viruses, illustrating commonalities in the requirements
for replication of these NS RNA viruses.
Although VSV is phylogenetically more closely related to
HPIV3 than LCMV (42), only 27 of the 72 factors identiﬁed for
VSV were required for HPIV3, whereas 54 of those were required
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infected with VSV (0.5 MOI) for 4 h. M protein levels from three experiments are shown as mean ± SD. (C) Cells transfected with ARF1 siRNAs were infected
with LCMV or HPIV3 (as in Fig. 3I). Viral gene expression was examined by immunoblotting for eGFP or GFPrr. (D) Cells transfected with GBF1 siRNAs for 72 h
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Fold change in mRNA and anti-genome levels were determined as in Fig. 3H. Mean ± SEM (n = 2) is shown. (G) GBF1 siRNA transfected cells were infected with
LCMV or HPIV3, and viral gene expression was measured as described in Fig. 3I. (H and I) Cells infected with 1 MOI of LCMV (H) or HPIV3 (I) were treated at
1 hpi with the drugs. Viral gene expression was assessed by immunoblotting for eGFP or GFPrr at 7 (LCMV) or 14 (HPIV3) hpi.
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We then used inhibitors of GBF1 to probe its requirement in
VSV gene expression. Brefeldin A (BFA) inhibits GBF1, BIG1
(brefeldin-inhibited guanine nucleotide exchange factor 1), and
BIG2, whereas Golgicide A (GCA) and Tyrphostin AG1478 are
speciﬁc inhibitors of GBF1 (39, 40). In the presence of these drugs,
VSV gene expression was inhibited (Fig. 4 E and F). The drugs had
no signiﬁcant adverse effects on viability of uninfected cells (Fig.
S5). We then examined VSV gene expression in Madin Darby
canine kidney (MDCK) cells, which contain a natural mutation
(M832L) in GBF1, rendering the cells resistant to BFA, GCA, and
AG1478 (39–41). However, in these cells, BIG1 and BIG2 are
sensitive to BFA (40). In MDCK cells infected with VSV, viral
gene expression was not adversely affected, even at higher concentrations of the drugs (Fig. S6C). Studies with VSVΔG virus
infection (Fig. S6D) and NC transfection (Fig. S6E) showed that
GBF1 is required for VSV gene expression. In LCMV and HPIV3
infected cells, viral gene expression was reduced after depletion of
GBF1 (Fig. 4G) and was sensitive to GBF1 inhibitors (Fig. 4 H and
I), indicating that GBF1 is also required for these viruses.

Since COPI is involved in endosomal transport (34), it is possible that the inhibition of VSV gene expression could be due to
disruption of endosomal transport required for VSV entry and
uncoating. However, inhibition of viral gene expression was observed
in NC-transfected cells depleted of COPI subunits (Fig. 3F), suggesting that COPI is required for viral gene expression, independent
of entry and uncoating steps. Additionally, we found reduced levels of
mRNA (transcription product) and anti-genome (replication product) in COPZ1-depleted cells (Fig. 3G). Furthermore, when cells
were treated with CBM 1 h after VSV infection, a time-frame in which
the majority of the virus would have uncoated their NCs (35), reduced
levels of mRNA and anti-genome were also observed (Fig. 3H),
suggesting that COPI is required for VSV gene expression.
We then examined whether COPI is also required for gene
expression of LCMV and HPIV3. Cells treated with siRNA for
COPI subunits were infected with GFP-encoding LCMV or
HPIV3. The level of GFP protein was examined in cell extracts
collected at the earliest time point when GFP expression was seen
in infected cells (7 hpi for LCMV or 14 hpi for HPIV3) (26).
Depletion of the COPI subunits (except COPE) signiﬁcantly
inhibited LCMV and HPIV3 gene expression (Fig. 3I), suggesting
that these viruses also require COPI functions.

GRM2

ARHGAP23

Cell membrane anchor

VSV-M

Entry

ADAL
GPCR
signaling

GABBR2

Endocytosis

Assembly
Stress
response

VSV-G
transport

OR7A10
RAB5C P2RY10 TAS2R48

RIT2
SDF4

PKMYT1

Genome

COPB1

Golgi

N

ATP6AP2

Uncoating

Vesicular
transport

ER

L

Transcription

Nucleus

Genome
NHP2L1

Replication
ATP6V0D1

DCAF13
UTP11L

EIF3A
Cytoskeletal
dynamics

Translation
regulation

EIF3I

HNRPK
RNA
processing

UTP6

TOX

Transcription
regulation

H1FOO
FOXF2

FCF1

ZNF446
NOP56

MAT2A

PPP1R15B
BBC3 BCL2L2

KCNH4

NRL

IFI35

FBL

PPP5C

EIF3G

Anti-genome

CRMP1

ARF1

COPZ1

VSV-G

SYVN1

G

COPA

GBF1

ARCN1
COPG

P
M

TIPIN

ERN2

COPB2

ATP6V0B

CEACAM7

CARD14

APR3

FRS2

SLC9A3 SLC46A1

FAU

ATPIF1
UQCRC1

HSPA9B

LAMC3

Mitochondria

Solute transporter

Cell adhesion

Fig. 5. Integrated model of host factors required for VSV, LCMV, and HPIV3. Genes were placed at positions most likely relevant to VSV infection. Subcellular
localization and biological functions of the proteins were determined by using Entrez Gene, Entrez PubMed, and UniProt. Genes shown as green circles are
shared by all three viruses, whereas genes shown as red circles are either for VSV only or shared by VSV and LCMV or by VSV and HPIV3.

for LCMV. We noted an enrichment of proteins involved in GPCR
signaling, indicating that signaling through some of these GPCR
components may be required for infection. The observations that
SLC46A1 (PCFT) is speciﬁcally required in entry/uncoating,
ADAL is required for assembly/budding, and MAT2A is required
for gene expression of VSV are unique ﬁndings of this study.
ADAL was recently discovered as a putative plasma membrane
protein closely related to adenosine deaminase with unknown
function. Further studies are required for understanding the molecular mechanisms of its involvement in VSV infection. Identiﬁcation of MAT2A, in VSV RNA synthesis, suggests its possible
involvement in VSV mRNA cap formation during transcription.
Whether these identiﬁed proteins are directly involved in various
steps in VSV infection or whether they mediate their activities
through other cellular interacting partners (Fig. S7) is of interest
for a mechanistic understanding of their role in VSV infection.
The subunits of COPI complex emerged strongly as factors required for infection by all three viruses. The heptameric COPI
complex associates with the Golgi membranes, resulting in the
budding of COPI-containing vesicles, whose major function is to
mediate transport of cellular proteins and cargo from the Golgi to
the ER as well as the intra-Golgi transport (20). Depletion of
COPI also perturbs the steady-state distribution of the Golgi
enzymes (43) and thus inhibits processing of the VSV G protein
and its transport to the plasma membrane (44, 45). Further, we
have found that depletion of COPZ1 subunit had no adverse effect
on VSV G protein-mediated entry of pseudotyped HIV (Fig. S8),
consistent with recent studies that BFA has no signiﬁcant effect on
VSV G-mediated entry of retrovirus (46). The following observations suggest that COPI is involved in VSV gene expression: (i)
VSV gene expression is inhibited in COPI-depleted cells that are
independent of the viral G protein processing, (ii) pharmacologic
19040 | www.pnas.org/cgi/doi/10.1073/pnas.1113643108

inhibitor of COPI inhibits VSV gene expression as well as viral
RNA levels, and (iii) VSV gene expression is reduced in NC
transfected cells that have been depleted of COPI.
Multiple siRNA screens for inﬂuenza virus, an NS RNA virus
that replicates in the nucleus, have identiﬁed COPI, but not
COPII, as required for infection (11, 12, 24). Although COPI is
required for inﬂuenza as well as VSV G-mediated virus entry (12),
our results for VSV are in contrast to these studies. It is possible
that the assay conditions, cell type used, and other unknown factors may have contributed to these disparate results. In this report
and also in earlier reports (11, 15, 47), the siRNA for COPE did
not inhibit VSV and other virus infections, indicating that this
protein may not have been depleted sufﬁciently to observe the
effect or that COPE may be dispensable for COPI function in viral
infection (11, 15, 47). Transfection of siRNAs for COPII subunits
resulted in statistically nonsigniﬁcant reduction of VSV infection
(Fig. S9), indicating that COPII may not be required for VSV,
consistent with the result that it was also not identiﬁed in the inﬂuenza virus screens (11, 12, 24). Our results point toward a speciﬁc role of COPI in VSV gene expression. The requirement for
ARF1 and GBF1, the upstream activators of COPI assembly in
modulating VSV RNA levels, suggests a role for the host cell secretory pathway in the process. Whether the COPI complex is
directly involved in regulating the viral polymerase functions or
whether it may signal through downstream effectors required for
viral gene expression is of further interest.
The requirement of COPI for genome replication has been well
documented for positive-strand RNA viruses, which replicate in
association with cytoplasmic membranous structures (9, 15, 47).
Viruses such as polio, hepatitis C, and coxsackie modulate the
activities of ARF1, GBF1, and COPI for formation of intracellular
organelles for replication (48, 49). Vaccinia virus, a DNA virus,
Panda et al.
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by VSV and two other NS RNA viruses. The requirement for host
cell secretory pathway in infection by VSV, LCMV, and HPIV3
argues for a common mechanism by which this cellular pathway
modulates NS RNA virus replication.
Experimental Procedures
The high-throughput primary siRNA screen was performed by using the Qiagen
genome-wide siRNA library (Version 1.0). The validation screen was conducted
by using Dharmacon ON-TARGETplus pool of four siRNAs. Details of the screen
design, statistical analysis, hit identiﬁcation, and other experimental procedures
can be found in SI Experimental Procedures.
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requires COPI for its biogenesis, whereas HIV lacks a requirement
for COPI (33). The studies presented here reveal a requirement
for COPI in gene expression of VSV, and possibly other NS RNA
viruses, suggesting a critical role of this secretory pathway in RNA
virus infection. Most NS RNA viruses including VSV, LCMV, and
HPIV3, replicate in the cytoplasm. The replication organelles, if
any, for the cytoplasmically replicating NS RNA viruses are unknown. VSV replicates throughout the cytoplasm of infected cells
(7, 50), although studies do not rule out the existence of speciﬁc
replication organelles in the cytoplasm. Further biochemical and
ultrastructural studies in cells infected with VSV and other NS
RNA viruses will likely illuminate the nature of the replication
organelles for these viruses.
In conclusion, this study has identiﬁed several previously
undescribed candidates and pathways regulating infection of cells
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SI Experimental Procedures
Cells, Viruses, Virus Infections, and Virus Yield Determination. HeLa

(ATCC # CCL2), MDCK, and TZM-bl cells were maintained in
DMEM supplemented with 10% FBS and antibiotics. BHK-21
cells were maintained in MEM with 5% FBS. LCMVr3-GFP (1)
and HPIV3-GFP (2) were grown in BHK-21 cells and titrated in
HeLa cells by ﬂuorescent focus forming assay. Clonal stock of
VSV-eGFP was prepared by growing the virus in BHK-21 cells and
titrating in HeLa cells by plaque assay. VSV-PeGFPΔG virus has
been described (3). VSV yield was determined by plaque assay on
HeLa cells.
Antibodies. Anti-M (23H12) monoclonal antibody was from
Douglas Lyles (Wake Forest University, Winston-Salem, NC).
Anti-actin, anti-eGFP, and anti-Renilla reniformis-GFP (GFPrr)
antibodies were from Santa Cruz; anti-βCOP, anti-ζCOP, antiARF1, and MAT2A antibodies were from Sigma; anti-GBF1 antibody was from BD Science; and anti-SLC46A1 antibody was
from Abcam.
SDS/PAGE, Immunoblotting, and Quantitation. These procedures are
described (3). Quantitation of proteins detected in the blots was
performed by using Versadoc QuantityOne software (BioRad
Laboratories).
NC Preparation and Transfection. VSV-eGFP NCs were prepared,
and transfection was performed by using Lipofectamine 2000 as
described (3).
RNAi Screen. The primary screen was performed at the Duke
University RNAi screening facility by using the Qiagen genomic
siRNA library v 1.0 consisting of four distinct siRNAs (A, B, C, and
D) targeting 22,909 known and putative human genes. The four
siRNAs were grouped into two pools, with each pool containing two
siRNAs (set AB and set CD). This format resulted in seventy-four
384-well plates per set and a total of 148 plates for the entire screen.
This 2 × 2 pool design allowed each gene to be tested by two independent siRNA sets. AllStars nontargeting (NT) siRNA (Qiagen) was used as a negative control. Also, siRNAs targeting N and
L genes (two per gene) of VSV were synthesized and used as
additional positive control siRNAs. The sequences of the siRNAs
targeting the VSV genes are as follows. N1: 5′-CUGCAAGGCCUAAGAGAGA-3′; N2: 5′-UGGAAUACCCGGCAGAUUA3′; L1: 5′-GCAGUUAUCCAGCAAUCAU-3′; and L2: 5′-GAGAAACGUUGUAGAAUUA-3′.
Corning 384-well tissue culture plates were prearrayed with 1
pmol of siRNA per well by using the Velocity Bravo liquid handling
system (Agilent Technologies). Each plate was also seeded with
siRNAs targeting VSV N and L gene as well as the NT siRNA.
Lipofectamine RNAiMAX (Invitrogen) was used in the amount of
0.05 μL per well in 10 μL of OptiMEM (Invitrogen). Reverse
transfection of 3,000 HeLa cells was performed with 15.4 nM ﬁnal
concentration of siRNAs in a 65 μL of total volume. VSV-eGFP
virus (grown in BHK-21 cells and titrated in HeLa cells) was used.
Initial studies of siRNA transfections (48 and 72 hpt), virus infections at different MOIs (0.2, 0.4, 0.5, 0.6, 0.8, 1, 2, and 3 MOI),
and for various lengths of time postinfection (8, 10, 12, 14, 16, and
18 h) were conducted to identify suitable conditions for primary
high-throughput screen. To identify factors involved in all stages of
the VSV life cycle, such as entry and uncoating, replication, and
budding and release, the screen was optimized for MOI and time
to allow multiple rounds of virus infection to occur. As a quality
Panda et al. www.pnas.org/cgi/content/short/1113643108

control metrics for the assay, Z′ factor (4) was calculated between
NT siRNA treated wells and N and L siRNA treated cells. The
multiplicity and time of infection was optimized to obtain a Z′
factor value of >0.5, which would indicate a robust assay. Based on
these initial standardization experiments, the genome-wide screen
was performed by using 0.5 MOI of VSV and 18 h of infection. In
the genomic screen, the Z′ factor between NT and L was calculated to be 0.44 for AB set and 0.51 for CD set. These Z′ factor
values indicated that we would be able to distinguish the positive
control wells (L and N siRNA treated cells) from control NT
siRNA treated wells in both AB pool and CD pool.
Automated Image Analysis. At the end of the infection, cells were
ﬁxed with 4% paraformaldehyde in PBS, permeabilized with 0.1%
Triton X-100 in PBS, and stained with Hoechst 33342 in PBS for 30
min. Stained cells were imaged with a Cellomics ArrayScan VTI
automated microscope. Images were analyzed with vHCS Scan
Target Activation software v 5.1.2 to identify infected cells. Cells
without VSV-eGFP infection served as reference population for
background ﬂuorescence. Four ﬁelds per well of a 384-well plate
were imaged at 10× magniﬁcation. First, cells were identiﬁed by
their nuclei staining in channel 1 of Cellomics. Cells that scored
positive in channel 1 were analyzed for GFP expression in channel
2, and GFP intensity was calculated for the cells. Frequency distribution of GFP intensity was plotted and compared between NT
siRNA transfected controls infected with VSV-eGFP or uninfected reference population. For selection of infected cells,
threshold was set by manual inspection of representative images
from VSV-eGFP infected and uninfected cells. Cells appearing at
least 5 SDs away from the average intensity of uninfected control
population in the same plate or same batch were considered
positive for GFP expression. Once the threshold was determined,
all of the plates were subjected to data analysis by vHCS Target
activation software. Finally, data were obtained by using vHCS
View software v 5.1.2, and the numbers of cells present in the well
were identiﬁed as “Valid Object Count” (VOC), whereas the
percentage of infection was determined as “% selected.”
Statistical Analysis. Transfection of siRNAs and subsequent infection with VSV resulted in reduced cell number for some wells
due to the combined effects of siRNA toxicity, loss of cell survival
factors, and VSV cytopathogenicity. We used a cutoff value of 800
or more cell number in four ﬁelds per well for further analysis. This
criterion requires that wells transfected with siRNA sets AB and CD
for a particular gene should have a VOC of at least 800. Using this
criterion, we discarded ~24% of the genes in the library. Because
our screen was designed to identify factors whose depletion would
reduce VSV infection, the genes discarded from further analysis
due to reduced cell numbers may potentially represent restriction
factors and/or factors required for cell survival. In other words, if
a gene is required for VSV infection, its depletion would reduce
VSV replication and thus would not promote VSV-mediated cell
death. We would then expect to observe higher cell number in
those wells. So, rationally, the remaining 76% of the genes in the
library should include factors required for VSV replication.
In the screen, for both AB set and CD set, we did not observe a
correlation between percent infection and cell number [r (correlation coefﬁcient) = 0.308 (for AB set) and 0.295 (for CD set)]. It
has been reported that cell density may impact clathrin-mediated
endocytosis and may subsequently affect virus infection (5).
However, throughout the primary screen, we used a cell density
(3,000 plated cells per well) and MOI (0.5) as well as time (18 hpi)
1 of 7

conditions in which the rate of infection remained in the linear
range. The distribution of percent infection for genomic population for the AB and CD pools did not follow a normal distribution, and thus parametric tests would not have given meaningful
results. Therefore, we used a nonparametric analysis, the Sum rank
statistics (6), to identify the hits from the primary screen. Because
of day-to-day variation in percent infection of NT control population, we decided to use batch-wise analysis to get the primary
hits. Percent infection values for set AB and set CD were ranked
independently from lowest to highest and given ranks from 1 to n
(n = the number of samples analyzed), respectively. Sum rank for
a particular gene is the sum of rank in AB set and rank in CD set for
that gene. The P value for each gene was then determined, and
ﬁnally samples were aligned according to the P value. A total of 233
genes with P < 0.01 were identiﬁed as primary candidate hits.
Validation Screen. The validation screen was conducted at the
Eppley Institute for Cancer Research at the University of
Nebraska Medical College (UNMC) by using Dharmacon ONTARGETplus pool of four siRNA. The sequences of Dharmacon
siRNAs did not overlap with those of Qiagen siRNAs, allowing us
to test multiple siRNA. The assay was conducted by using 96-well
plates. Six microliters of pooled siRNA (500 nM) was prearrayed
per well in 96-well plates by using the Biomek FX liquid handling
system. Lipofectamine RNAiMAX and OptiMEM mix was
prepared (0.25 μL of LipofectamineRNAiMAX in 20 μL of
OptiMEM per well). For experiments using VSV, 15,000 cells in
75 μL of DMEM with 10% FBS and 1× PKS per well were added
to each well to yield a ﬁnal concentration of 30 nM siRNAs. For
LCMV and HPIV infection, 10,000 cells per well were added in
75 μL of above medium. Cells were incubated for 50 h for
knockdown of the genes. For VSV-eGFP infection, 0.05 MOI of
virus was added in 100 μL of DMEM 2% FBS and 1× PKS per
well by using a multichannel pipette. LCMVr3-GFP (0.05 MOI)
and HPIV3-GFP (0.2 MOI) were used to infect HeLa cells.
Virus inoculum containing required MOI of viruses were prepared in 40 μL of DMEM (with 5% FBS and PKS) per well.
After 1 h of infection, 60 μL of DMEM with 5% FBS and 1×
PKS was added to each well. Cells were infected with VSV for
14 h, with LCMV for 36 h, or with HPIV3 for 41 h. Infected cells
were ﬁxed as per the protocol described in the primary screen.
Cells were stained with DAPI to stain the nuclei. Image analysis
was performed in Cellomics ArrayScan VTI at UNMC to obtain
the VOC and percent infection. Experiment was repeated four
times for VSV and two times each for LCMV and HPIV3.
Meaningful between-plate comparisons required normalization
due to variations among plates. Therefore, we normalized the
percent infection values by plate-wise medians, separately for
siRNA-treated and untreated control samples. We applied the
nonparametric Wilcoxon-Mann-Whitney (WMW) rank-sum test
(7). Despite the lower statistical power of the nonparametric
tests compared with the parametric tests, the WMW test indicated signiﬁcant effects of the siRNA treatment in the majority
of genes compared with untreated controls at the P ≤ 0.01 level.
Normalization was performed by in-house PERL and MATLAB
programs. The WMW tests, heat map representations, and other
graphics were carried out in MATLAB.
siRNA Transfection in 12-Well Plate. Reverse transfection of HeLa
cell was performed in 12-well tissue culture plates. Final concentrations of siRNAs were 20 nM, except for COPI where 10 nM
concentrations of siRNAs were used. Required amount of siRNAs
were plated in the wells. Lipofectamine RNAiMAX in OptiMEM
was prepared (2 μL of Lipofectamine in 300 μL of OptiMEM per
well) and added to the wells. Plates were incubated for 30 min
for complex formation. HeLa cells (200,000 cells per well in 500
μL of DMEM 10% FBS+ PKS) were added for COPI experiments. For other siRNA transfection experiments, 100,000 cells
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were added. Cells were further incubated for 42–44 h for COPI
siRNAs and 66–68 h for other siRNA transfection. All of the
experiments were conducted with Dharmacon ON-TARGETplus siRNAs, except that where indicated, the Qiagen siRNAs
were used.
Quantitative RT-PCR (qRT-PCR). qRT-PCR was used to measure the
VSV P mRNA, genome, and anti-genome levels. Total RNA was
extracted from cells by TRIzol according to manufacturer’s
protocol (Invitrogen). First-strand cDNA was synthesized from
200 ng of total RNA by using M-MLV reverse transcriptase
according to manufacturer’s protocol (Invitrogen). For quantiﬁcation of P mRNA and the internal control β-actin mRNA,
oligo-(dT) was used as primer in one RT reaction. For quantiﬁcation of anti-genome and the internal control β-actin mRNA,
VSV2955R and β-actin1 R (each 2 pmol) were used as primers
in another RT reaction. These cDNAs were used as templates in
qRT-PCR reactions that were carried out in Cepheid Smart
Cycler. The sequences and optimized concentrations of the primers and probes are listed in Tables S1 and S2, respectively.
Lightcycler 480 probe master mix (Roche Applied Sciences) was
used in qRT-PCR reactions. The thermal setup conditions used
included initial denaturation at 95 °C for 5 min, denaturation at
95 °C for 30 s, and annealing and extension at 60 °C for 30 s for
a total of 40 cycles. Relative fold change in VSV P mRNA and
anti-genome levels was calculated by ΔΔCt method. Brieﬂy, the
difference in threshold cycle (ΔCt) was calculated by dividing Ct
value of VSV P mRNA or anti-genome with Ct value of the
respective β-actin internal control. The relative fold change in
VSV P mRNA or anti-genome levels was calculated by dividing
the ΔCt value of siRNA treated sample with ΔCt value of NT
siRNA-treated sample.
Semiquantitative RT-PCR. VSV N mRNA and anti-genome levels
were examined as described in our previous publication (3).
Cell Viability Measurement. Cell viability was measured by CellTiter
Glo assay (Promega). Brieﬂy, 30,000 cells were plated per well in a
clear bottom black wall 96-well plate. Cells were treated with the
indicated concentrations of the drugs in 100 μL of volume and
further incubated for the appropriate length of time. One hundred microliters of CellTiter Glo reagent was added to the wells
and incubated at room temperature for 10 min. Readings were
taken by using a luminometer.
HIV Pseudotype Experiment. For this experiment, pHIV NL4-3based, GFP-expressing reporter construct (8) was used. To generate
virus stock, 293T cells were cotransfected with an envelope (VSVG or HIV NL4-3) expressing plasmid, along with an Env-deﬁcient,
pHIV NL4-3. HeLa or TZM-bl cells were reverse transfected with
siRNAs against COPZ1, COPG, or ATP6V0B. For COPZ1 and
COPG transfection, cells were incubated for 28–30 h before infection. For ATP6V0B, cells were incubated for 52 h before infection. The siRNA transfected cells were infected with 1.0 × 105
TCID50 VSV-G pseudotyped (HeLa) or NL4-3 env packaged
(TZM-bl) virus stock, and GFP-positive cells were measured by
ﬂow cytometry (BD FACScan) at 40 hpi. To enhance the infectivity
with the NL4-3 env packaged HIV, TZM-bl cells were exposed to
DEAE dextran (33.3 μg/mL) simultaneously with virus for 3.5 h.
Cells were washed two times with PBS and supplemented with
DMEM plus 10% FBS and incubated for 37 h more.
Protein–Protein Interaction Network. Protein–protein interaction
network data were downloaded from the STRING Database (9)
and manually validated for each interaction. Each network was
represented by using the Cytoscape suite (10) as follows: the focal
protein for each network (COPA, MAT2A, SCL46A1, and ADAL)
and their respective subunits were color-coded and aligned hori2 of 7

zontally. Network visualizations were redrawn by centering to these
focal proteins and their subunits and to preserve the topologies of

most other highly interconnected subnetworks to the highest possible extent.
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Fig. S1. Computational pathway analysis of identiﬁed factors. (A) Ingenuity pathway analysis (IPA; Ingenuity Systems) identiﬁed 8 top biological functional
annotations associated with the 173 identiﬁed candidates. Integration of these functions is presented in the form of relationships as direct (solid lines) and
indirect (discontinuous lines) interactions with arrows indicating the direction of the underlying relationship when appropriate. The nodes with gray background represent molecules identiﬁed in our screen, and those with white background are the molecules forecasted by IPA knowledge base. (B) Biological
processes enriched among the 72 genes identiﬁed in the validation screen for VSV were compared with those identiﬁed for other viruses (1–8). Hit lists were
accessed from these published articles and subjected to the Panther biological classiﬁcation analysis. The color intensities represent degree of requirement by
the indicated virus. Red and gray represent high degree of dependency. Blue represents little or no dependency on the indicated pathway or process.
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Fig. S2. vATPase is required for VSV infection. (A) Cells were transfected with pool of four siRNAs for indicated vATPase subunits for 72 h and infected with
VSV (MOI = 0.01) for 14 h. Cell extracts were examined for VSV gene expression (viral M protein) by immunoblotting. Actin is shown for loading control. (B)
HeLa cells were transfected with the indicated siRNAs and then infected with VSVΔG virus. M protein expression was examined at 5 hpi. (C) Cells transfected as
above were treated with (+) or without (−) baﬁlomycin A1 (Baf A1) for 30 min and then transfected with VSV NC. VSV gene expression (M protein) was
examined by immunoblotting at 6 h after NC transfection.

MAT2A

NT

Dx4

Dx3

Dx2

Dx1

NT

Dx4

Dx3

Dx2

B

Qiagen

Dharmacon

Dx1

NT

A

mRNA

M

Actin

Anti-genome

SLC46A1

GAPDH

Fig. S3. SLC46A1 and MAT2A are required for VSV infection. (A) HeLa cells transfected with individual siRNA duplexes targeting SLC46A1 were subsequently
infected with 0.005 MOI of VSV for 14 h. Cell lysates were collected and the viral M protein, actin, and SLC46A1 were examined by immunoblotting. (B) HeLa
cells were transfected with pool of four siRNAs targeting MAT2A and at 48 hpt were infected with VSV. At 4 hpi, levels of mRNA and antigenomic RNAs were
determined as described (1). Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was shown as internal control.
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Fig. S4. Effect of depletion of COPI subunits on VSV gene expression. (A) HeLa cells transfected with individual siRNA duplexes targeting COPB1 subunit and
subsequently were infected with VSV (MOI = 0.5) for 4 h. VSV gene expression was assessed by immunoblotting for M. Depletion of COPB1 was examined by
Western blotting. (B) HeLa cells transfected with individual siRNA duplexes (four per gene) targeting each of the seven COPI subunits were infected with VSV
(MOI = 0.5) for 4 h. VSV gene expression was assessed by immunoblotting for M. Relative levels of M (mean ± SD) from three experiments are presented.

Fig. S5. Cell viability after drug treatment. (A) HeLa cells plated in 96-well plate were treated with Brefeldin A (BFA; 5 μg/mL), Golgicide A (10 μM), or AG-1478
(30 μM) for 6 h or CBM (2 mM) for 4 h. Cell viability was measured by CellTiter-Glo assay. (B) Cells plated as described in A were treated with BFA (200 ng/mL),
Golgicide A (5 μM), or AG-1478 (20 μM) for 14 h. Cell viability was measured as described in A.
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Fig. S6. Disruption of ARF1 and GBF1 functions affects VSV RNA synthesis. (A and B) HeLa cells were treated with pool of four siRNAs for ARF1 (A) or GBF1 (B)
and then infected with VSV. VSV-P mRNA or anti-genome levels were examined by qRT-PCR. Values show mean ± SE of measurement (SEM) of duplicate
reactions from two experiments after normalizing to NT control. (C) MDCK cells infected with 1 MOI of VSV were treated with indicated concentrations of the
drugs at 1 hpi. Cell lysates were prepared at 4 hpi, and M and actin levels were assessed by immunoblotting. Relative levels of M (mean ± SD) compared with
vehicle controls from three experiments are presented. (D and E) HeLa cells depleted of GBF1 protein by pool of four siRNAs were infected with VSVΔG virus (D)
or transfected with NCs (E). M protein expression was examined at 5 hpi (D) or 6 hpt (E).

Fig. S7. Protein-protein interaction networks. The protein–protein interaction network for solute carrier family 46, member 1 protein (SLC46A1; protoncoupled folate transporter, PCFT) (A), ADAL (B), MAT2A (C), and COPI (D). Edges (interactions) are indicated by red colors. Only the proteins directly interacting
with SLC46A1, ADAL, MAT2A, and COPI and their directly interacting proteins are shown. Interactions and annotations were obtained from the STRING
Database (1) and from GeneCards (2), and network visualizations were created using Cytoscape (3).
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Fig. S8. Depletion of COPI does not affect VSV-G mediated HIV entry. (A) COPZ1, COPG, or ATP6V0B siRNAs transfected HeLa cells or TZM-bl cells were
infected with VSV-G pseudotyped HIV or NL4-3 env packaged virus, respectively. GFP expressing cells were measured by ﬂow cytometry at 40 hpi. Asterisk
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Fig. S9. Transfection of COPII siRNA does not affect VSV infection. HeLa cells were transfected with siRNAs for SEC13L1 and SEC23A (two of the COPII
subunits) or against COPZ1. At 48 hpt, cells were infected with VSV (MOI = 0.01), and normalized percent infection relative to NT siRNA at 16 hpi was
determined.

Table S1. Primer sequences
Primer

Sequence

VSV 2795F
VSV2860R
VSV2955R
β-Actin-F
β-Actin-R
VSV 2825 probe
β-Actin probe

Table S2.

GTGACGGACGAATGTCTCATAA
TTTGACTCTCGCCTGATTGTAC
TGATGAATGGATTGGGATAACA
CAAGTACTCCGTGTGTGGAT
CATACTCCTGCTTGCTGAT
6-FAM/CCATCCTGCTCGGCCTGAGATAC/TAMRA
Cy5/TCGCTGTCCACCTTCCAGCAGAT/BHQ

Primer and probe concentrations

Primer

Primer concentrations, nM

VSV P mRNA
VSV 2795-F
VSV 2860-R
VSV anti-genome
VSV 2795-F
VSV 2955-R
β-Actin
β-Actin-F
β-Actin-R

Probe

Probe concentrations, nM

500
500

VSV 2825

200

1,000
1,000

VSV 2825

200

500
500

βActin

1,000

Dataset S1. List of genes identiﬁed in the primary screen for VSV
Dataset S1
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Dataset S2. List of genes identiﬁed for VSV, VSV/LCMV/HPIV3, VSV/LCMV, or VSV/HPIV3
Dataset S2

Dataset S3. Known and putative biological functions and subcellular localization of genes required for VSV
Dataset S3
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